Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades

Vista sencilla de ítem
dc.contributor.advisorGonzález Aguirre, Irene
dc.contributor.advisorIglesias Acosta, Jesús
dc.contributor.authorCarrillo Navarro, María Claudia
dc.contributor.authorGuerrero García, Augusto Santiago
dc.coverage.spatialBarranquillaspa
dc.creator.emailmariaclaudia_2401@yahoo.es, asguerrero2013@gmail.com
dc.creator.emailmariaclaudia_2401@yahoo.esSPA
dc.creator.emailasguerrero2013@gmail.com SeccionalSPA
dc.date.accessioned2017-07-26T19:02:54Z
dc.date.available2017-07-26T19:02:54Z
dc.date.created2016
dc.description.abstractLa tromboembolia representa una importante causa de morbimortalidad, siendo la anticoagulación el pilar del tratamiento. Los anticoagulantes orales directos, constituyen una opción que supera algunos de los inconvenientes con warfarina, como la monitorización rutinaria. No obstante con su inclusión en la práctica clínica, surgieron otras limitaciones: la dificultad para su medición cuando se requiere, debido a la poca disponibilidad y estandarización de pruebas hemostáticas; y la falta de antídotos para reversión, frente a hemorrágicas severas. Sin embargo recientemente fue aprobado idarucizumab, un anticuerpo monoclonal que neutraliza al dabigatrán, no disponible en Colombia. Se concluye que estos fármacos, son una opción atractiva, que requieren el desarrollo de pruebas diagnósticas y agentes de reversión específicos accesibles. Se realizó una búsqueda en bases de datos como Pubmed, Clinical Key, Embase, Evidence- Based MEDICINE, con las palabras clave dabigatrán, rivaroxabán, apixabán, monitorización, sangrado. Se incluyó literatura en idioma inglés y español entre 1998-2016.spa
dc.description.abstractThromboembolism is a major cause of morbidity and mortality, with anticoagulation being the mainstay of treatment. The direct oral anticoagulants are an option to overcome some of the drawbacks of warfarin, such as routine monitoring. Nevertheless, new constraints have emerged by their inclusion in clinical practice: the difficulty in measuring, due to the limited availability and standardization of hemostatic tests; and the lack of antidotes for reversal, to deal with severe bleeding. However, idarucizumab was recently approved, it’s a monoclonal antibody that neutralizes dabigatran, but is not available in Colombia. We concluded that these drugs are an attractive option, which require the development of diagnostic tests and available specific reversal agents. We made the research on databases such as Pubmed, Clinical Key, Embase, Evidence-Based Medicine, with keywords dabigatran, rivaroxaban, apixaban, monitoring, bleeding. We include the literature in English and Spanish language between 1998 and 2016.Eng
dc.formatPDF
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad Librespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad Librespa
dc.identifier.urihttps://hdl.handle.net/10901/10236
dc.language.isospa
dc.relation.referencesMozaffarian D, Roger Vl, Benjamin BJ, Berry JD, Blaha MJ, et. al. Heart disease and stroke. Statistics—2014 Update A Report From The American Heart Association. Circulation. 2014; (129): 399-410.eng
dc.relation.referencesMiyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna Wp, et al. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 To 2000, And Implications On The Projections For Future Prevalence. Circulation. 2006; 114:119–25eng
dc.relation.referencesEzekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Mayo Clin Proc. 2004: 79:904–13.eng
dc.relation.referencesSudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet.1998; 352:1167–71.eng
dc.relation.referencesHart R, Diener H, Shelagh B, Coutts MD,Donald Easton J, Granger C, O'donnell M, et al. Embolic strokes of undetermined source: The case for a new clinical construc. The Lancet Neurology. 2014; (13): 429-438.eng
dc.relation.referencesKernan WN, Chair MD, Ovbiagele B, Chair V, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack a guideline for healthcare professionals from the American heart association/american stroke association. Stroke. 2014. (45):1-77.eng
dc.relation.referencesBhupathiraju SN, Hu FB, et al. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118(11):1723-35.eng
dc.relation.referencesMarín F, Sánchez P, Cortina JM, García JA, Jiménez D, Lecumberri R, et al. Comentarios a la guía de práctica clínica de la ESC 2014 sobre el diagnóstico y tratamiento de la embolia pulmonar aguda Rev Esp Crdaridoilo. 2015; 68 (1): 10- 16.eng
dc.relation.referencesPaul D, Stein Md Y Fadi Matta Md. Epidemiology and Incidence: The scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin Volumen 2011; 907–932eng
dc.relation.referencesStein PD, Matta F. Acute pulmonary embolism. Curr Prob Cardiol 2010; 35:314–76.eng
dc.relation.referencesUbaldini J, Chertcoff J, Sampó E, Casey M, Ceresetto J, Boughen R. Consenso de enfermedad tromboembólica- consenso argentino sac. Revista Argentina De Cardiología. 2009; 77(5): 411-428.eng
dc.relation.referencesDennis R, Rojas MX, Molina A, Roa J, Granados M, Londoño A, et al. Clinical course and survival in pulmonary embolism results of the Colombian multicentric registry (emepco). Acta Médica Colombiana. 2008 Volumen (33 N° 3): 111-116.eng
dc.relation.referencesJanuary C, Wann S, Alpert J, Field M, Calkins H, Murray K, et al. Aha/Acc/Hrs guideline for the management of patients withatrial fibrillationa report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014; (129:000–000)eng
dc.relation.referencesHart R, Lesly A. Pearce, et al. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-867.eng
dc.relation.referencesFernández M, Rueda Y, Villa V, Belmonte S, Stoyanova A. Análisis del perfil sociosanitario del paciente anticoagulado en España. Federación Española De Asociaciones De Anticoagulados. 2013.eng
dc.relation.referencesBrummel K, Kenneth G. Molecular basis of blood coagulation. En: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York USA. Elsevier. 2013; 1821-1841.eng
dc.relation.referencesKang-Ling W, Pao-Hsien C, Cheng-Han L, Pei-Ying P, Pao-Yen L, Kou-Gi S, et al. Management Of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Act Cardiol Sin. 2016; 32:122.eng
dc.relation.referencesAguilar M, Hart R, Pearce L. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patientswith non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007; (6): 186- 198eng
dc.relation.referencesFontana P, Robert-Ebadi H, Bounameaux H, Boehlen F, Righini M. Direct oral anticoagulants: A Guide For Daily Practice. Medical Intelligence. 2016; 146:W14286.eng
dc.relation.referencesBaglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. J Thromb Haemost 2013; 11: 756–60.eng
dc.relation.referencesFontana P, Goldhaber S, Bounameaux H. Anticoagulantes orales directas en el tratamiento y la prevención a largo plazo del tromboembolismo venoso. Eur Heart J. 2014; 35: 1836-43.eng
dc.relation.referencesAlbadalejo G, García J, Lopez MF, Roldán V. Guía Sobre Los Nuevos Anticoagulantes Orales Sociedad Española de Hematología Y Hemoterapia / Sociedad Española De Trombosis Y Hemostasia.eng
dc.relation.referencesPautas E, Monti A, Breining A. Farmacología clínica comparada de los anticoagulantesorales: Avk Y Nuevos Anticoagulantes. Tratado de Medicina, Elsevier 2015; 19(1):1-5.eng
dc.relation.referencesVanden D, Peetermansb M, Vanasscheb T, Verhamme P, Vandermeulen E. Monitoring and reversal strategies for new oral anticoagulants. Expert Review Of Cardiovascular Therapy. 2015; 13:95-103.eng
dc.relation.referencesArribalzaga K, Asenjo S, Cesar J, Llamas Y, Oña F. Rodríguez AM, et al. Guía de uso de dabigatrán etexilato (pradaxa®) en la prevención del ictus y embolismo sistémico en los pacientes con fibrilación auricular no valvular y otros factores de riesgo. Asociación Madrileña De Hematología Y Hemoterapia (AMHH). 2012SPA
dc.relation.referencesParamo JA. New Oral Anticoagulant Agents: The quandary of anticoagulation in the elderly. Medicina Clínica (Barc). 2013.eng
dc.relation.referencesPollack Ch, Jr. et al. Antidotes for bleeding caused by novel oral anticoagulants. Circulation. 2016; 133:18-19.eng
dc.relation.referencesWeitz Ji, Eikelboom Jw, Samama Mm; American College of Chestphysicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2): 120-151eng
dc.relation.referencesGómez A, Lecumberri R. Antidotes for the new oral anticoagulants: Reality and expectations. Medicina Clínica (Barc). 2016.SPA
dc.relation.referencesHolster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145:105–112.eng
dc.relation.referencesFreeman W, Aguilar I, Weitz J. Risk of intracerebral bleeding in patients treated with anticoagulants. Uptodate. 29 De Oct De 2013.eng
dc.relation.referencesVidal-Jordana I, Barroeta-Espar MP, Sáinz Pelayo J, Delgado-Mederos M, Martí-Fàbregas J. Hemorragias intracerebrales en pacientes anticoagulados, ¿qué hacemos después? Neurología. 2012; 27 (3):136—142.eng
dc.relation.referencesFlaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116—21eng
dc.relation.referencesDiener Hc, Connolly Sj, Ezekowitz Md, Wallentin L, Reilly Pa, Yang S, et al, For The Re-Ly Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the re-ly trial. Lancet Neurol. 2010; 9:1157-63.eng
dc.relation.referencesMorgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41: p 2108—29.eng
dc.relation.referencesGarcía F, Dalmau B. La medicina actual ante los anticoagulantes de nueva generación. Med Clin (Barc). 2012; 138(10): p 438–440eng
dc.relation.referencesSan Miguel J, Sánchez-Guijo F. Fisiopatología De La Coagulación. En: San Miguel, Jesús F. Hematología: Manual Básico Razonado, Tercera Edición: España; Elsevier. 2009: 19; 199-212.eng
dc.relation.referencesMarfil LJ. Fisiología de la Coagulación I. Función Plaquetaria. En: José Carlos Jaime Pérez, David Gómez Almaguer. Hematología la sangre y sus enfermedades. Segunda Edición. México, D.F. McGraw-Hill; 2009; 137-143.eng
dc.relation.referencesJonathan W, Yau Hwee Y, Subodh V. Endothelial cell control of thrombosis. Bmc Cardiovasc Disord. 2015; 15: 130.eng
dc.relation.referencesKenneth G, Mann Y, Kathleen E, Brummel Z. Normal coagulation. En: Jack L. Cronenwett, K. Wayne Johnston. Rutherford's Vascular Surgery. Eighth Edition. Philadelphia USA. Elsevier; 2014. P 528-548.eng
dc.relation.referencesVan Hinsbergh Vw. Endothelium–Role in regulation of coagulation and inflammation. Semin Immunopathol. 2012; 34: 93–106.eng
dc.relation.referencesRachel C, Danczyk Y Timothy K. Liem. Hemostasis and thrombosis. En: Moore, Wesley. Vascular and Endovascular Surgery: A Comprehensive Review, Eighth Edition. Philadelphia USA. Elsevier; 2014. P 68-87.eng
dc.relation.referencesHall JE. Hemostasis and blood coagulation. En: Guyton and Hall Textbook of Medical Physiology, Thirteenth Edition. Jackson, Mississippi. Elsevier; 2016. P 483-494.eng
dc.relation.referencesGordon D.O, Lowey C. Bagot. Hemostasis and thrombosis. En: John W Baynes y Marek H Dominiczak. Medical Biochemistry Fourth Edition. Columbia, South Carolina Usa. Elsevier; 2014. 68-81.eng
dc.relation.referencesCarvalhoy M, Loscalzo J. Normal Mechanisms of Vascular Hemostasis. En: Creager, Mark A. Vascular Medicine: A companion to braunwald's heart disease, second edition. Boston, massachusetts. Elsevier; 2013. P. 70-74.eng
dc.relation.referencesDavi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: P. 2482-2494eng
dc.relation.referencesHajjar C, Esmon N, Marcus AJ, Muller A. Función Vascular En La Hemostasia. En: Marshall A. Lichtman, Keneth Kaushaky, Thomas J. Kipps, Josef P. Prchal. Marcel M. Levi. Williams Manual De Hematología. Octava Edición. Mcgraw-Hill; 2014. p. 1451-1470eng
dc.relation.referencesItaliano J, Hartwig J. Megakaryocyte and Platelet Structure. In: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York USA. Elsevier; 2013. 1797-1808eng
dc.relation.referencesbrams Ch, Plow E, Charles S. Molecular Basis for Platelet Function. In: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York Usa. Elsevier; 2013. p. 1809-1820.eng
dc.relation.referencesParise L, Smyth S, Coller B. Morfología, bioquímica y función de las plaquetas. En: Marshall A. Lichtman, Keneth Kaushaky, Thomas J. Kipps, Josef P. Prchal. Marcel M. Levi. Williams Manual De Hematología. Octava Edición. Mcgraw-Hill; 2014. p. 1357-1408.eng
dc.relation.referencesPatel-Hett S, Richardson Jl, Schulze H, et al: Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood 2008; 111: p. 4605.eng
dc.relation.referencesItaliano Je, Richardson Jl, Patelhett S, et al: Angiogenesis is regulated by a novelmechanism: proand antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: Pp. 1227eng
dc.relation.referencesBluteau D, Lordier L, Di Stefano A, et al: Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009; 7: 227eng
dc.relation.referencesCrawley J, Scully M, Zhang X. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. American Society of Hematology 2013.eng
dc.relation.referencesZhang X, Halvorsen K, Zhang CZ, Wong WP, Springer Ta. Mechanoenzymatic cleavage of the ultralarge vascular protein von willebrand factor. Science. 2009; 324 (5932):1330-1334.eng
dc.relation.referencesFeys HB, Anderson PJ, Vanhoorelbeke K, Majerus Em, Sadlerje. Multi-Step Binding Of Adamts-13 to Von Willebrand Factor. J Thromb Haemost. 2009; 7(12):2088-2095.eng
dc.relation.referencesFuller Gl, Williams JA, Tomlinson Mg, et al. The C-type lectin receptors clec-2 and dectin-1, but not dc-sign, signal via a novel -dependent signaling cascade. J Biol Chem 2007; 282: 12397eng
dc.relation.referencesBertozzi C, Schmaier AA, Mericko P, et al. platelets regulate lymphatic vascular development through Clec-2-Slp-76 signaling. Blood 2010; 116: 661.eng
dc.relation.referencesMay F, Hagedorn I, Pleines I, et al. Clec-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009; 114: 3464eng
dc.relation.referencesWang Y, Litvinov RI, Chen X, et al. Loss of pipkigamma, unlike other pipki isoforms, impairs the integrity of the membrane cytoskeleton in murine megakaryocytes. J Clin Invest 2008; 118: 812.eng
dc.relation.referencesAngiolillo Dj, Ferreiro Jl. Inhibición del receptor plaquetario p2 y 12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Rev Esp Cardiol. 2010; 63: 60-76.eng
dc.relation.referencesLópez A, Macayaa C. Plaqueta: Fisiología de la activación y la inhibición. Rev Esp Cardiol. 2013; 13: 2-7.SPA
dc.relation.referencesAlvarado I. Fisiología de la coagulación: nuevos conceptos aplicados al cuidado perioperatorio. Univ. Méd. 2013; 54: 338-352.SPA
dc.relation.referencesDavie EW, Ratnoff SI. Waterfall sequence for intrinsic blood clotting. Science. 1964; 145:1310-2.eng
dc.relation.referencesKriz N, Rinder C, Rinder H. Physiology of hemostasis: with relevance to current and future laboratory testing. Clinics in Laboratory Medicine, Vol. 29, Issue 2. p. 159–174.eng
dc.relation.referencesWilliams JC, Mackman N. Tissue factor in health and disease. Front Biosci (Elite Ed) 2012; 4: 358.eng
dc.relation.referencesAngiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010; 31: 17-28eng
dc.relation.referencesMateo J, Santamaria A, Fontcuberta J. Fisiología y exploración de la hemostasia. En: J. Sans-Sabrafen C. Besses Raebel J.L. Vives Corrons. Hematología Clínica. Quinta Edición. Madrid España. Elsevier. 2007; 659-681.SPA
dc.relation.referencesErev E. Tubb, Mckenzie E. Trastornos de la hemostasia y la trombosis. En: Waldman, Scott A, Laurence J. Egan, Frcpi, Jean-Luc Elghozi, et al. Pharmacology and therapeutics: principles to practice, First Edition. Copyright © 2009 By Saunders, An Imprint Of Elsevier Inc. Chapter 63, 909-919.eng
dc.relation.referencesWeitz Ji. Heparan Sulfate: Antithrombotic or not? J Clin Invest 2003; 111:952.eng
dc.relation.referencesGiri TK, Ahn CW, Wu KK, et al. Heparin cofactor ii levels do not predict the development of coronary heart disease: the atherosclerosis risk in communities (Aric) Study. Arterioscler Thromb Vasc Biol 2005; 25: 2689eng
dc.relation.referencesBroze Gj Jr, Girard Tj. Tissue factor pathway inhibitor: structure-function. Front Biosci. 2012: 17: 262–280.eng
dc.relation.referencesKasthuri RS, Glover Sl, Boles J, et al. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost 2010; 36: 764.eng
dc.relation.referencesBode Mf, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2014; 35.eng
dc.relation.referencesMarx PF, Brondijk TH, Plug T, Romijn RA, Hemrikaw, Meijers JC, Huizinga Eg. Crystal structures of tafi elucidate the inactivation mechanism of activated tafi; a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803–9.eng
dc.relation.referencesRezaie Ar: regulation of the protein c anticoagulant and antiinflammatory pathways. Curr Med Chem 2010; 17: 2059.eng
dc.relation.referencesisse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon Ct, Teyton L, Petersen Lc, Ruf W. The endothelial protein c receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem. 2011; 286: 5756–5767.eng
dc.relation.referencesKonopatskaya O, Matthews SA, Harper MT, Gilio K, Cosemans JM, Williams CM, Navarro MN, Carter DA, Heemskerk JW, Leitges M, Cantrell D, Poole AW. Protein kinase c mediates platelet secretion and thrombus formation through protein kinase D2. 2011; 118: 416–424.eng
dc.relation.referencesVersteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013; 93:327–58.eng
dc.relation.referencesRijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: P 4-13.eng
dc.relation.referencesCastellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647–54.eng
dc.relation.referencesCastellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647–54.eng
dc.relation.referencesAdam SS, Key NS, Greenberg CS. Antígeno del Dímero D: Conceptos actuales y perspectivas de futuro. Sangre 2009; 113: 2878.eng
dc.relation.referencesRighini M, Perrier A, De Moerloose P, et al: D Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6: 1059.eng
dc.relation.referencesHuber K. Plasminogen activator inhibitor type1 (part two): role for failure of thrombolytic therapy. Pai1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis 2001; 11: 195.eng
dc.relation.referencesFoley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008; 283: 8863–7.eng
dc.relation.referencesBertina Rm, Van Tilburg NH, Haverkate F, Bouma BN, Von Dem-Borne PA, Meijers JC, Campbell W, Eaton D, Hendriks DF, Willemse Jl. Discovery of thrombin activatable fibrinolysis inhibitor (Tafi). J Thromb Haemost 2006; 4: 256–7.eng
dc.relation.referencesGuimaraes AH, Laurens N, Weijers EM, Koolwijk P, Van Hinsbergh VW, Rijken DC. Tafi and pancreatic carboxypeptidase b modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27:2157–62.eng
dc.relation.referencesFoley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation offibrinolysis. J Biol Chem 2008; 283: 8863–7.eng
dc.relation.referencesChristiansen VJ, Jackson KW, Lee KN, Mckee PA. The Effect of a Single nucleotide polymorphism in the alpha-2-antiplasmin human activity. Blood 2007; 109: 5286.eng
dc.relation.referencesLaw RH, Sofian T, Kanwt H, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-Ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049–52.eng
dc.relation.referencesLaw RH, Sofian T, Kanwt, Horvathaj, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049–52.eng
dc.relation.referencesMann KG, Brummelziedins K, Orfeo T, et al: Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108.eng
dc.relation.referencesHoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003; 17(1): S1-S5.eng
dc.relation.referencesMann KG. Thrombin generation in hemorrhage control and vascular occlusion. Circulation 2011; 124: 225.eng
dc.relation.referencesMonroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler. Thromb Vasc Biol. 2006; 26: 41–48.eng
dc.relation.referencesStavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, Brinkman HJ, Meijer AB, Mertens K. Factor seven activating protease (Fsap): does it activate factor VII? J Thromb Haemost. 2012:10: 859–866.eng
dc.relation.referencesOwens Iii AP, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep. 2012; 14:394–401.eng
dc.relation.referencesRuf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor andcell signalling in cancer progression and thrombosis. J Thromb Haemost. 2011; 9(1): 306–15.eng
dc.relation.references. Versteeg HH, Heemskerk JJ, Levi M, Reitsma H. new fundamentals in hemostasis. Physiol Rev. 2013; 93: 327–358.eng
dc.relation.referencesGómez OA, Melgarejo E. Anticoagulación. Sociedad Colombiana De Cardiología y Cirugía Cardiovascular. Junta Directiva 2003-2005.SPA
dc.relation.referencesQuintero-González JA, cincuenta años de uso clínico de la warfarina. Invest Clin. 2010; 51(2): 269 - 287.SPA
dc.relation.referencesGeorge M, Brenner Y, Craig W, Stevens Phd. Anticoagulant, antiplatelet, and fibrinolytic drugs. En: Pharmacology. Fourth Edition. Tulsa, Oklahoma. Elsevier. 2013: 156-167.eng
dc.relation.referencesLaurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann, Goodman G. Las bases farmacológicas de la terapéuticas 12ed. México: Interamericana Mcgraw-Hill Interamericana Editores 2012: 30:857-866SPA
dc.relation.referencesTadros R, Shakib S. Warfarin--Indications, risks and drug interactions. aust famphysician. [En Línea] 2010 Jul [Consultado Set 2012]; 39(7): 476-9. Disponible En: Http://Www.Racgp.Org.Au/Afp/201007/201007tadros_Warfain.PdfSPA
dc.relation.referencesFlórez J, Sedano M.C. Farmacología de la hemostasia, la coagulación y la fibrinólisis. En: Florez J, Armijo J, Mediavilla A. Farmacología Humana. 3a Ed. Barcelona: Masson S.A.; 1997. Cap. 46: 794-803.SPA
dc.relation.referencesGarcía F, Dalmau B. La medicina actual ante los anticoagulantes de nueva generación. Medicina Clínica. Med Clin (Barc). 2012; 138(10):438–440SPA
dc.relation.referencesYurgakya J, Rodríguez F. Warfarina: uso contemporáneo. Revista Med. 2009: 17 (1): 107-115.SPA
dc.relation.referencesBarnes. W, Ageno J, Ansell S, kaatz T. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 13: 1154–1156.eng
dc.relation.referencesMateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Revista Española Cardiología Supl. 2013; 13(C):33-41.SPA
dc.relation.referencesVan Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran Etexilate--A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.eng
dc.relation.referencesEscolar E, García J, López MF, Roldán V. Guía sobre los nuevos anticoagulantes orales. Sociedad española de hematología y hemoterapia / sociedad española de trombosis y hemostasia. 2012.SPA
dc.relation.referencesKubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G: Safety, Pharmacodynamics, and pharmacokinetics of single doses of bay 59- 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-421.eng
dc.relation.referencesProm R, Spinler Sa: The role of apixaban for venous and arterial thromboembolic Disease. Ann Pharmacother 2011; 45(10):1262-1283.eng
dc.relation.referencesEma. Ficha Técnica Rivaroxabán (Xarelto). Http://Www.Ema.Europa.Eu/Docs/Es_Es/Document_Library/Epar_Product_Inform ation/Human/000944/Wc500057108.Pdf. 2012.eng
dc.relation.referencesFicha Técnica Dabigatrán (Pradaxa). Http://Www.Ema.Europa.Eu/Docs/Es_Es/Document_Library/Epar__Product_Infor mation/Human/000829/Wc500041059.Pdfeng
dc.relation.referencesEma. Ficha Técnica Apixabán (Eliquis).Http://Www.Ema.Europa.Eu/Docs/En_Gb/Document_Library/Epar_Produc t_Information/Human/002148/Wc500107728.Pdf 2012.SPA
dc.relation.referencesAltman R. Los Nuevos Anticoagulantes Orales (Nacos). ¿Pongr qué debemos controlar su actividad anticoagulante? Rev Fed Arg Cardiol. 2014; 43(2): 60SPA
dc.relation.referencesYou JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2): 531S-75S.eng
dc.relation.referencesCamm A, Gregory Y.H. Lip. Raffaele De Caterina. Savelieva. Dan Atar. Stefan H. Hohnloser, et al. Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. Rev Esp Cardiol. 2013; 66(1):54.e1-e24.eng
dc.relation.referencesConnolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. For the RE-LY steering committee and investigators. Dabigatran Versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.eng
dc.relation.referencesPatel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. For the ROCKET AF investigators. Rivaroxaban Versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91eng
dc.relation.referencesConnolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. For The AVERROES steering committee and investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806.eng
dc.relation.referencesGranger CB, Alexander JH, Mcmurray JJ, Lopes RD, Hylek EM, Hanna M, et al, For the ARISTOTLE committees and investigators. Apixaban Versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.eng
dc.relation.referencesMega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt D, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.eng
dc.relation.referencesEriksson BI. Dahl OE. Huo MH. Kurth AA. Hantel S. Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105(4): 721-9.eng
dc.relation.referencesLassen R, Raskob GE, Gallus A, Pineo G, Chen D. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010: 375: p807–815.eng
dc.relation.referencesEriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A, et al. Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty. RECORD1. N Engl J Med 2008; 358: 2765-2775.eng
dc.relation.references. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.eng
dc.relation.references. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.eng
dc.relation.references. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.eng
dc.relation.referencesLassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Rivaroxaban T. versus Enoxaparin for thromboprophylaxis after total knee arthroplasty. RECORD 3.N Engl J Med 2008; 358:2776-2786.eng
dc.relation.referencesTurpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet. 2009; 373(9676): 1673-80.eng
dc.relation.referencesSchulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-52.eng
dc.relation.referencesBauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS. et al. Einstein investigators. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-510.eng
dc.relation.referencesLozano FS. Nuevos anticoagulantes orales en el tratamiento de la trombosis venosa profunda. Angiología. 2012; 64(5):212---217.eng
dc.relation.referencesBauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS. et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012; 366:1287-129.eng
dc.relation.referencesAgnelli G, Harry R, Bulle D, Cohen A. Curto M, Gallus A. Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799- 808.eng
dc.relation.referencesGiuseppe Lippi J, Favaloro J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clin Chem Lab Med 2015; 53(2): 185–197.eng
dc.relation.referencesStangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamic of oral dabigatran etexilate. Clin Pharmacol 2010; 49:259-268.eng
dc.relation.referencesKitchen S, McCraw A, Echenagucia M. Preparación y calibración de un pool de plasma normal (PPN). Diagnóstico de la hemofilia y otros trastornos de la coagulación. Manual de Laboratorio Segunda edición Publicado por la Federación Mundial de Hemofilia (FMH). 2010.eng
dc.relation.referencesDouxfils J, Mullier F, Robert S, et al: Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: pp. 985-997.eng
dc.relation.referencesHawes EM, Funk-D Adcock, Gosselin R, Jeanneret C. Cook AM, Taylor JM. et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013; 11(8):1493-502.eng
dc.relation.referencesCushman M, Lim W, Zakai NA. Clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults. The American Society of Hematology; 2011[http://222.hemataology.org/Practice/Guidelines/2934.aspx. Pblished 2011. Accessed 11Feb2015].eng
dc.relation.referencesJones S.D., Eaddy N.S., Chan G.T. Dabigatran: laboratory monitoring. Pathology 2012; 44: pp. 578-580eng
dc.relation.referencesTripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban- treated patients: results of an in vitro study. J Thromb Haemost 2011; 9: 226–8. 12.eng
dc.relation.referencesZafar M, Vorchheimer D, Gaztanaga J, Velez M, Yadegar D, Moreno P, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007 Oct; 98(4):883-8eng
dc.relation.referencesArribalzaga K, Asenjo S, Pérez C, Llamas P, Oña F, Rodriguez AM, et al. Guía de uso de rivaroxabán (Xarelto®) en la prevención del ictus y embolismo sistémico en los pacientes conm fibrilación auricular no valvular y otros factores de riesgo. Asociación Madrileña de Hematología y Hemoterapia (AMHH). Diciembre 2012.SPA
dc.relation.referencesWeitz J, Connolly S, Patel I, Salazar D, Rohatagi S, Mendell J. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep; 104(3):633-41.eng
dc.relation.referencesCuker A, Siegal D, Crowther M, García D. Laboratory measurement of the anticoagulant activity of the non–vitamin K oral anticoagulants. Journal of the American College of Cardiology. 2014; 6 4: 1128–1139.eng
dc.relation.referencesOrtiz G, Ariza F, Trujillo G, Bejaranob A, Gutiérrez JM, Gálvese K, et al. Manejo del sangrado y la coagulación en la prácticaclínica. Evaluación de la 107 evidencia y recomendacionesmediante estrategia GRADE. Primera reuniónde expertos. Acta Colomb Cuid Intensivo. 2016.SPA
dc.relation.referencesChai-Adisaksopha C, Hillis T, Isayama W, Lim A, Iorio M, Crowthe. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2015; 13: pages 2012–2020.eng
dc.relation.referencesTemboury F, Buforn M, Cabrera-Bueno F. New oral anticoagulants: Management bleeding complications. Cardiocore. 2014; 49(3):102–104eng
dc.relation.referencesLabrador J, González-Porras R. ¿Qué hacer ante una complicación hemorrágica en pacientes tratados con nuevos anticoagulantes orales? Angiología. 2015; 67(2):118-124.SPA
dc.relation.referencesNeena S, Abrahama, Castillo D. Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol 2013; 29:676–683.eng
dc.relation.referencesMarano G, Vaglio S, Pupella S, Liumbruno G, Franchini M. How we treat bleeding associated with direct oral anticoagulants. Blood Transfus. 2016; 0180- 15.eng
dc.relation.referencesZhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebralhemorrhage associated with the direct thrombin inhibitor dabi-gatran. Stroke. 2011; 42: 3594.eng
dc.relation.referencesEerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatranby prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573.eng
dc.relation.referencesVan Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the directthrombin inhibitor dabigatran, by recombinant factor VIIa oractivated prothrombin complex concentrate. Haematologica.2008; 93(s1):148. Abs.O370eng
dc.relation.referencesPollack C, Reilly P, Eikelboom J, Glund S, Verhamme P, Bernstein R, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-52.eng
dc.relation.referencesSiegal D, Curnutte J, Connolly S, Lu G, Conley P, Wiens B, et al. Andexanet Alfa for the Reversal of Factor X Inhibitor Activity. N Engl J Med 2015; 373:2413- 24.eng
dc.relation.referencesNiessner A, Tamargo J, MoraisJ, Koller J, Wassmann S, Elkjær Husted S, et al. Reversal strategies for non-vitamin k antagonist oral anticoagulants: a critical 108 appraisal of available evidence and recommendations for clinical management—a joint position paper of the european society of cardiology working group on cardiovascular pharmacotherapy and european society of cardiology working group on thrombosis. European Heart Journal Advance Access published December 24, 2015.eng
dc.relation.referencesSiega D, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis April 2013, Volume 35, Issue 3, pp 391-398.eng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa
dc.rights.licenseAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subjectAnticoagulantesspa
dc.subjectTromboemboliaspa
dc.subjectTromboemboliaspa
dc.subjectTromboemboliaspa
dc.subjectMedicamentosspa
dc.subject.lembHEMORRAGIAspa
dc.subject.lembDABIGATRÁNspa
dc.subject.lembRIVAROXABÁNspa
dc.subject.lembAPIXABÁNspa
dc.subject.proposalDabigatránspa
dc.subject.proposalRivaroxabánspa
dc.subject.proposalApixabánspa
dc.subject.proposalMonitorizaciónspa
dc.subject.proposalSangradospa
dc.subject.subjectenglishDabigatraneng
dc.subject.subjectenglishRivaroxabaneng
dc.subject.subjectenglishApixabaneng
dc.subject.subjectenglishMonitoringeng
dc.subject.subjectenglishBleedingeng
dc.titleAnticoagulantes orales directos: monitorización y reversión, dos grandes dificultadesspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1fspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesisspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localTesis de Especializaciónspa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
MONOGRAFIA DE MONITORIZACION Y REVERSION DE DOACs.pdf
Tamaño:
2.3 MB
Formato:
Adobe Portable Document Format
Descripción:
Trabajo de Grado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización en Medicina Interna